Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study

N. Bejanyan*, M.J. Zhang, K. Bo-Subait, C. Brunstein, H.L. Wang, E.D. Warlick, S. Giralt, T. Nishihori, R. Martino, J. Passweg, A. Dias, E. Copelan, G. Hale, R.P. Gale, M. Solh, M.A. Kharfan-Dabaja, M.A. Diaz, S. Ganguly, S. Gore, L.F. VerdonckN.M. Hossain, N. Kekre, B. Savani, M. Byrne, C. Kanakry, M.S. Cairo, S. Ciurea, H.C. Schouten, C. Bredeson, R. Munker, H. Lazarus, J.Y. Cahn, M. van der Poel, D. Rizzieri, J.A. Yared, C. Freytes, J. Cerny, M. Aljurf, N.D. Palmisiano, A. Pawarode, V.U. Bacher, M.R. Grunwald, S. Nathan, B. Wirk, G.C. Hildebrandt, S. Seo, R.F. Olsson, B. George, M. de Lima, C.S. Hourigan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)
Original languageEnglish
Number of pages9
JournalTransplantation and Cellular Therapy
Volume27
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • AML
  • MDS
  • DRI
  • Myeloablative
  • RIC
  • ACUTE MYELOID-LEUKEMIA
  • STEM-CELL TRANSPLANTATION
  • UNRELATED DONOR TRANSPLANTATION
  • TERM-FOLLOW-UP
  • REDUCED-INTENSITY
  • WORKING PARTY
  • REGIMENS
  • IMPACT
  • MUTATIONS

Cite this